Clinical and immunological studies of human fibroblast interferon. 1982

K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D005260 Female Females
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast

Related Publications

K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
May 1983, Gan no rinsho. Japan journal of cancer clinics,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
January 1983, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
April 1984, Mutation research,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
January 1980, Pharmacology & therapeutics,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
November 1978, Cancer treatment reports,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
April 1981, Nihon Gan Chiryo Gakkai shi,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
January 1981, Methods in enzymology,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
January 1983, Hybridoma,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
February 1966, Die Medizinische Welt,
K Ezaki, and M Ogawa, and K Okabe, and K Abe, and K Inoue, and N Horikoshi, and J Inagaki
June 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!